Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC

PURPOSE: Osimertinib was initially approved for T790M positive NSCLC and, more recently, for first-line treatment of EGFR-mutant NSCLC. However, resistance mechanisms to osimertinib have been incompletely described. EXPERIMENTAL DESIGN: Using cohorts from MD Anderson Lung Cancer Moonshot GEMINI and...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Le, Xiuning, Puri, Sonam, Negrao, Marcelo V., Nilsson, Monique B., Robichaux, Jacqulyne, Boyle, Theresa, Hicks, J. Kevin, Lovinger, Katherine L., Roarty, Emily, Rinsurongkawong, Waree, Tang, Ming, Sun, Huiying, Elamin, Yasir, Lacerda, Lara C., Lewis, Jeff, Roth, Jack A., Swisher, Stephen G., Lee, J.Jack, William, William N., Glisson, Bonnie S., Zhang, Jianjun, Papadimitrakopoulou, Vassiliki A., Gray, Jhanelle E., Heymach, John V.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6295279/
https://ncbi.nlm.nih.gov/pubmed/30228210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1542
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi